Page last updated: 2024-08-22

cladribine and Influenza, Human

cladribine has been researched along with Influenza, Human in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	3 (75.00)	2.80

Authors

Authors	Studies
Battistini, L; Furlan, R; Moiola, L; Nicoletti, F; Riva, A; Salvetti, M; Uccelli, A	1
Boschert, U; Centonze, D; Chudecka, A; Oreja-Guevara, C; Roy, S; Schmierer, K; Wiendl, H	1
Aslan, D; Hagenacker, T; He, X; Kleinschnitz, C; Kleinschnitz, K; Korsen, M; Meuth, SG; Oezalp, SH; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Skuljec, J; Su, C	1
Helbig, G; Kyrcz-Krzemien, S; Pająk, J; Wieczorkiewicz, A; Woźniczka, K	1

Reviews

1 review(s) available for cladribine and Influenza, Human

Article	Year
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Neurodegenerative disease management, 2023, Volume: 13, Issue:1 Topics: Chickenpox; Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets	2023

Article

Year

A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets.

Neurodegenerative disease management, 2023, Volume: 13, Issue:1

Topics: Chickenpox; Cladribine; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets

2023

Other Studies

3 other study(ies) available for cladribine and Influenza, Human

Article	Year
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. Current neuropharmacology, 2022, Volume: 20, Issue:10 Topics: Cladribine; COVID-19; Humans; Immunosuppressive Agents; Influenza, Human; Multiple Sclerosis; SARS-CoV-2; Tablets; Vaccination	2022
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine. Cells, 2023, 04-25, Volume: 12, Issue:9 Topics: Antibody Formation; Cladribine; Humans; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza Vaccines; Influenza, Human; Multiple Sclerosis; Seasons; Vaccination	2023
Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4 Topics: Amoxicillin; Anemia, Aplastic; Anti-Infective Agents; Antineoplastic Agents; Antiviral Agents; Aspergillosis; Bone Marrow; Ciprofloxacin; Cladribine; Humans; Influenza A Virus, H1N1 Subtype; Influenza, Human; Leukemia, Hairy Cell; Male; Oseltamivir; Pancytopenia; Pandemics; Pneumonia, Viral; Young Adult	2011